title: Inherited prothrombotic risk factors in Turkish children with acute lymphoblastic leukemia: significance of concomitant genetic mutation.
abstract: Our study was designed to prospectively evaluate the role of the methylenetetrahydrofolate reductase (MTHFR) TT677 genotype, the prothrombin (PT) 620210A mutation, the factor V G1691A mutation in leukemic Turkish children treated according to modified BFM 95 study protocols with respect to the onset at thromboembolic events. Eighty-two consecutive leukemic children investigated had are established inherited prothrombotic risk factor: 29 children showed the MTHFR genotype (heterozygous, n = 22; homozygous, n = 7); 3 showed the heterozygous PT G20210A variant; 16 were carriers of the factor V mutation (heterozygous). In addition, combined prothrombotic defects were found in a further 11 patients the MTHFR mutation was combined with the F V mutation (n = 7), the PT G20210A variant (n = 2). In 7 (8.5%) of these 82 patients, venous thromboembolism occurred. In conclusion, the presence of inherited thrombophilia with Turkish children treated acute lymphoblastic leukemia may be useful for designing targeted primary prevention strategies.
authors.affiliation: Department of Pediatric Hematology, State Educational and Research Hospital of the Government, Kayseri, Turkey. yaseminaltuner@yahoo.com
authors.forename: Yasem'n Altuner
authors.initials: YA
authors.lastname: Torun
authors.forename: Turkan
authors.initials: T
authors.lastname: Patiroglu
authors.forename: Mehmet Akif
authors.initials: MA
authors.lastname: Ozdemir
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Ozkul
authors.forename: Arzu
authors.initials: A
authors.lastname: Ekici
authors.forename: Musa
authors.initials: M
authors.lastname: Karakukcu
mesh_terms: D020413:3' Untranslated Regions / Q000235:genetics; D020016:Activated Protein C Resistance / Q000453:epidemiology / Q000235:genetics; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D015897:Comorbidity; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005165:Factor V / Q000235:genetics*; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D009154:Mutation; D017354:Point Mutation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D011516:Prothrombin / Q000235:genetics*; D019851:Thrombophilia / Q000453:epidemiology / Q000235:genetics*; D014421:Turkey / Q000453:epidemiology; D056824:Upper Extremity Deep Vein Thrombosis / Q000453:epidemiology / Q000209:etiology; D020246:Venous Thrombosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D020413:3' Untranslated Regions; C095381:factor V Leiden; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D005165:Factor V; D011516:Prothrombin; D011239:Prednisolone; D015122:Mercaptopurine; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin